Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.43 |
| ▸ | MAP3K8 | P41279 | 7/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.40 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | STAT3 | P40763 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2038308 | 0.85 | FGFR1 (0.56) | HCAR1FGFR1MAP3K8GABRA1GABRG2 | |
| SCHEMBL28755487 | 0.85 | HCAR1 (0.43) | HCAR1FGFR1MAP3K8GABRA1GABRG2 | |
| SCHEMBL2036319 | 0.84 | PRKCI (0.42) | HCAR1FGFR1MAP3K8GABRA1GABRG2 | |
| SCHEMBL2034246 | 0.83 | MAP3K8 (0.50) | FGFR1MAP3K8 | |
| SCHEMBL2035276 | 0.82 | ALDH1A1 (0.56) | FGFR1MAP3K8GABRA1GABRG2GABRB3 | |
| SCHEMBL2030247 | 0.82 | PDPK1 (0.46) | HCAR1FGFR1MAP3K8GABRA1GABRG2 | |
| SCHEMBL2034994 | 0.82 | MAPT (0.47) | MAP3K8ALDH1A1HTTGFER | |
| SCHEMBL2036240 | 0.82 | HCAR1 (0.41) | HCAR1FGFR1MAP3K8GABRA1GABRG2 | |
| SCHEMBL2033748 | 0.76 | MAP3K8 (0.46) | FGFR1MAP3K8HTTCYP1A2 | |
| SCHEMBL2038322 | 0.75 | HCAR1 (0.46) | HCAR1FGFR1MAP3K8GABRA1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7998972-B2 | 1H-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases | NOVARTIS AG (CH) | 2011-08-16 | — | — | US | claimed |
| JP-4707389-B2 | — | — | 2011-06-22 | — | — | JP | claimed |
| CN-100475207-C | 1H-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases | NOVARTIS AG (CH) | 2009-04-08 | — | — | CN | claimed |
| US-20050245562-A1 | 1h-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases | NOVARTIS AG (CH) | 2005-11-03 | — | — | US | claimed |
| CN-1655788-A | 1H-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases | NOVARTIS AG (CH) | 2005-08-17 | — | — | CN | claimed |
| EP-1509521-A2 | 1H-IMIDAZO[4,5-C]QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | Novartis AG (CH) | 2005-03-02 | — | — | EP | claimed |
| WO-2003097641-A2 | 1H-IMIDAZO[4,5-C] QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2003-11-27 | — | — | WO | claimed |
| CN-100475207-C | 1H-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases | NOVARTIS AG (CH) | 2009-04-08 | — | — | CN | disclosed |
| EP-1509521-B1 | 1H-IMIDAZO[4,5-C]QUINOLINE DERIVATIVES FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2008-08-20 | — | — | EP | disclosed |
| CN-1655788-A | 1H-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases | NOVARTIS AG (CH) | 2005-08-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245562-A1 | 1h-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases | ABL1, PRKCA, PRKCQ | HCAR1 4108/4885FGFR1 3042/4885MAP3K8 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.